Neuland Laboratories

Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) headquartered in Hyderabad. Founded in 1984, the company produces active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs. Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange.

Overview

Neuland operates through two primary business verticals: Generic Drug Substances (GDS) and CDMO services. Its operations span process research and development, custom synthesis, scale-up, regulatory documentation support, and commercial manufacturing.

The company exports products to more than 80 countries and maintains approvals from major international regulatory authorities, including the United States Food and Drug Administration (US FDA), European Directorate for the Quality of Medicines (EDQM), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

As of 2025, Neuland employs approximately 2,000 people, including over 360 scientists engaged in research and development activities.

Product development

The company's operations are divided into three segments: Custom Manufacturing Solutions, which develops APIs from pre-clinical to commercial stages; Generic Drug Substances, which manufactures non-exclusive APIs; and a Peptide API unit that specializes in peptide synthesis.

Facilities

Neuland Laboratories operates multiple world-class facilities supporting active pharmaceutical ingredient (API), intermediate, and peptide production.

• Unit I – Bonthapally: The primary manufacturing hub situated in Bonthapally village, Medak District, Telangana, with multiple production blocks including kilo labs and quality assurance laboratories. It holds approvals from major regulatory agencies and supports commercial API production.
• Unit II – Pashamylaram: A large-scale manufacturing facility comprising multiple production blocks, an engineering workshop, and warehouses.
• Unit III – Gaddapotharam: A multi-product facility designed for advanced intermediates and APIs, with analytical development and pilot plant capabilities.
• Peptide Manufacturing Facility – Bonthapally: A dedicated state-of-the-art peptide facility under construction, featuring modular units and advanced automation to support scalable peptide production.
• R&D Centre – Bonthapally: Research and development centre with a team of approximately 360 scientists, pilot labs, and analytical capabilities to catalyze process development and technology transfer.

References